(Total Views: 737)
Posted On: 12/17/2020 8:15:53 PM
Post# of 151023
Tough patient population in that trial. All must have ARDS and be on ventilators.
I know in the past I made a post about MESO pointing out I was surprised they did so well with their emergency use COVID patients considering that remestemcel-L had absolutely no effect in a COPD trial. MESO investors were not happy with me.
I know in the past I made a post about MESO pointing out I was surprised they did so well with their emergency use COVID patients considering that remestemcel-L had absolutely no effect in a COPD trial. MESO investors were not happy with me.
(3)
(0)Scroll down for more posts ▼
